After nearly 30 years as a Community Clinical Oncology Program (CCOP) performing vital cancer research, the North Shore-LIJ Health System (NSLIJHS) is applying to become a Community Site as part of the National Cancer Institute's NCORP Program. Since its latest CCOP renewal, the NSLIJHS research program enrolled 1,300 subjects on cancer treatment, prevention and control trials, meeting or exceeding the required annual 60 treatment and 80 control credits for each grant year. The NSLIJHS NCORP program will offer local access to and data management support for almost 300 cancer research studies open to accrual through its affiliations with Alliance, the University of Rochester Cancer Center, the Wake Forest Cancer Center, NRG Oncology and other Research Bases through the Cancer Trials Support Unit (CTSU). As the NSLIJ CCOP transitions to an NCORP Community Site, its primary goal for the grant cycle will be to enhance its multifaceted partnership with NSLIJHS Divisions and NCORP Subcomponents in order to create a network of primary care and multi-specialty health professionals, community organizations, local governments and research base organizations that will (a) conduct cancer prevention, control, and screening/post-treatment surveillance clinical trials;(b) design and conduct multi-level cancer care delivery research;(c) enhance patient and provider access to treatment and imaging clinical trials;and (d) increase the participation of minorities, women and other underserved populations across all study types and settings. The NSLIJHS NCORP will be a multidisciplinary research unit. It will include 64 medical, radiation and surgical oncologist from Nassau, Suffolk and Queens Counties in New York. An additional 34 full time support staff including ONS and SoCRA certified nurses, data managers, research coordinators, regulatory staff and others will participate at a variety of locations across the catchment area. In 2012, NSLIJHS diagnosed and/or treated over 16,000 new cancers cases and accounted for nearly 30% percent of all cancer-related inpatient and ambulatory surgery discharges in New York's Queens, Nassau and Suffolk counties.

Public Health Relevance

The NSLIJ Health System's 2013 Community Health Needs Assessment identified cancer as a significant health priority in Queens, Nassau and Suffolk Counties in NYS. Research with community members and health care professionals identified increased outreach and collaboration between health care providers and local communities were effective and vital health improvement strategies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RTRB-E (M1))
Program Officer
Mccaskill-Stevens, Worta J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Feinstein Institute for Medical Research
United States
Zip Code
Zent, Clive S; Victoria Wang, Xin; Ketterling, Rhett P et al. (2016) A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908). Am J Hematol 91:308-12
Galindo, Rodolfo J; Romao, Isabela; Valsamis, Ageliki et al. (2016) Hypercalcemia of Malignancy and Colorectal Cancer. World J Oncol 7:5-12
Castillo, Jorge J; Mulkey, Flora; Geyer, Susan et al. (2016) Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials. Am J Hematol 91:199-204
Phillips, Kelly-Anne; Regan, Meredith M; Ribi, Karin et al. (2016) Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer 114:956-64
Rogers, C Leland; Perry, Arie; Pugh, Stephanie et al. (2016) Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539. Neuro Oncol 18:565-74
Page, Brandi R; Shaw, Edward G; Lu, Lingyi et al. (2015) Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue. Neuro Oncol 17:1393-401